Should stem cell therapy be used in DLCBL?
Response based on the findings of the case study presented by Prof. Marek Trnn Transcript: The question to consider is whether a stem cell transplant is su...
By: Emmet Dunne
Follow this link:
Should stem cell therapy be used in DLCBL? - Video
A/Professor Dr Chin on Stem Cell Therapy
Interview on Bernama TV - Dr Chin Sze Piaw, Consultant Physician Cardiologist SUBSCRIBE: http://www.youtube.com/BeverlyWilshir... FACEBOOK: http://face...
By: Beverly Wilshire
Visit link:
A/Professor Dr Chin on Stem Cell Therapy - Video
Differentiated stem cells into cardiac cells!
This video was uploaded from an Android phone.
By: Brandon dale
See the rest here:
Differentiated stem cells into cardiac cells! - Video
Stem Cell Therapy and Hair Transplantation Methods
Subscribe to Tv5 News Channel: http://goo.gl/NHJD9 Like us on Facebook: http://www.facebook.com/tv5newschannel Follow us on Twitter: https://twitter.co...
By: TV5 News
Visit link:
Stem Cell Therapy and Hair Transplantation Methods - Video
Heart Stem cell therapy
Clara answers some questions regarding the stem-cell therapy she received for congenital heart disease. For more info visit: http://www.stemaid.com.
By: stemaid
Continued here:
Heart Stem cell therapy - Video
Should stem cell therapy be used in DLBCL?
By: Lymphoma Hub
Follow this link:
Should stem cell therapy be used in DLBCL? - Video
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson http://www.docereclinics.com.
By: Harry Adelson, N.D.
See the original post:
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson - Video
The Philippines is the biggest market for the popular, if highly controversial, alternative treatment in Germany called fresh-cell therapy (FCT). Fresh cells derived from the fetus of an unborn lamb are injected into patients, and are said to cure a large number of illnesses.
Despite the high cost of the treatment, wealthy Filipinos are undeterred, and typically arrive in droves in a sleepy town outside Frankfurt, their hopes of being cured or rejuvenated pinned on the life of every donor sheep.
Given its renown, its no surprise that questions about the efficacy and safety of FCT has been the subject of discussions among health professionals. There have also been rumors of deaths after FCT.
The proponents of FCT in Germany, however, claim that all talk about patient deaths and questionable safety standards are unfounded, and an uncouth effort to discredit FCT so that the same medical professionals here could promote stem-cell therapy, which is allowed in the country. They deny the rumors of deaths and challenge their accusers to show proof. They also maintain that FCT is a decades-old, legitimate and safe naturopathic treatment.
Theres also a rivalry in Edenkoben between the famous clinic Villa Medica and the breakaway practice of Dr. Robert Janson-Mller, who used to work at the same clinic.
Dr. Mller now administers FCT in a hotel, which doubles as his clinic. This gave rise to talks questioning the standards of a practice that is done in a hotel, not a hospital. Some accounts also say that there have been Filipino patients fooled into believing they were bound for Villa Medica, only to find themselves in Dr. Mullers hotel.
Inquirer Lifestyle visits the two rival clinics in Germany, and we experience firsthand what FCT is all about.
Follow Us
Recent Stories:
Tags: Dr. Robert Janson-Mller , Frankfurt , fresh cell therapy , Stem Cell Therapy , Villa Medica
See the rest here:
The furor over fresh-cell therapy (which is NOT stem cell therapy)
Regenerative Medicine
Regenerative Medicine is a same-day, non-surgical adult stem cell procedure for treating common injuries and degenerative joint conditions. Hear how one pati...
By: ProMedica
View original post here:
Regenerative Medicine - Video
Poway, California (PRWEB) March 21, 2014
Ruby, a 10 year old Border Collie mix from Breckenridge, Colorado, has found relief from the pain of arthritis with stem cell therapy by Vet-Stem, Inc. Rubys owners came to Jamie Gaynor, DVM at Frisco Animal Hospital for a second opinion after being told Ruby would need a total hip replacement to relieve her constant pain and discomfort. Her quality of life had diminished so rapidly they feared losing her.
Dr. Gaynor began performing stem cell therapy by Vet-Stem for pets in 2006, in Colorado Springs. Paralleling his specialties in pain management, he has now helped well over one hundred pets in the state of Colorado, and ones that traveled just to have his expertise. His credentials and experience made Dr. Gaynor the perfect fit for helping Rubys worsening bilateral hip arthritis despite aggressive drug therapy. Ruby would become Dr. Gaynors first stem cell therapy case at Frisco Animal Hospital; Summit Countys first and oldest animal hospital.
Ruby was in constant pain and discomfort. She had to be carried up stairs and could not go on car rides; her second favorite thing to do. Her quality of life was diminishing rapidly, and we thought we were losing her, explained Rubys owners.
Rubys stem cell procedure consisted of a small fatty tissue collection, which was sent overnight to Vet-Stems lab in California for processing. Once Rubys fat was processed, and stem cells were extracted, fresh doses of her stem cells were sent overnight back to Dr. Gaynor in injectable doses. Within 48hrs of collecting a fat sample from Ruby, Dr. Gaynor was able to inject stem cells into each of her arthritic, painful hips, making Ruby his first stem cell therapy case in Summit County.
Dr. Gaynor and Rubys owners were both pleased with the successful outcome of the procedure, and had the opportunity to share during her 30 day recheck. Ruby is back! She has regained her playfulness, sassy, bossy, collie attitude. She has resumed going for car rides and can stand up and stabilize herself. She jumps out of the car without hesitation. She ascends and descends the stairs like she used to, her owners remarked about Rubys physical performance.
Her entire disposition and expressions are so animated and relaxed. I forgot how she used to smile, hold her ears up, and have endless energy. She is definitely out of pain, and her mobility is at 80%! The best part is, that she continues to heal and get stronger each week. This procedure is hands down the most effective, least traumatic therapy available, especially for the older dog, Rubys owners expressed.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Continue reading here:
Stem Cell Therapy for Pets in Summit County Colorado Proves to Be a Success for Local Dog Suffering from Pain
In India, stem cell biz may touch $8 b by 2015
Mumbai, March 21:
Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be an ideal supplement for existing medical treatments, he added.
Cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
We have a research unit in Malaysia that is conducting research on stem cells, Hamied said while speaking about Stempeutics Research with which it has an alliance. The Manipal Group-promoted Stempeutics is developing stem cell-based medicinal products with facilities in Kuala Lumpur (Malaysia) and Bangalore.
We are partners in the Bangalore company, he said. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market, he added.
Poised to reach an estimated $88.3 billion by 2015, the global stem cells market has been growing at a compounded annual growth rate of 14.8 per cent, driven by the increasing demand of stem cell therapy.
In India, the stem cell business is expected to touch $8 billion (48,880 crore today) by 2015. With three phase II clinical trials in progress in India for critical limb Ischemia (meaning restriction in blood supply to tissues), osteoarthritis and liver cirrhosis Stempeutics aims to bring the first product into the Indian and Malaysian markets by 2015.
Under the alliance, Cipla has invested over 50 crore in Stempeutics, with a focus on research of stem cell-based products, and has done something similar in China, where it has streamlined its investments towards its core business. The drug-maker recently exited a significant part of its investment in its Chinese partner Desano Holdings.
Despite the lack of legislation and awareness, besides quality and ethical issues that have deterred growth of the stem cell therapy business in India, the country remains the top priority for the Mumbai-based drug-maker, the Cipla Chairman told Business Line.
More here:
Cipla bets big on cell therapy
PUBLIC RELEASE DATE:
20-Mar-2014
Contact: Matthew Inlay minlay@uci.edu 949-824-8226 University of California - Irvine
Irvine, Calif., March 20, 2014 Hematopoietic stem cells are now routinely used to treat patients with cancers and other disorders of the blood and immune systems, but researchers knew little about the progenitor cells that give rise to them during embryonic development.
In a study published April 8 in Stem Cell Reports, Matthew Inlay of the Sue & Bill Gross Stem Cell Research Center and Stanford University colleagues created novel cell assays that identified the earliest arising HSC precursors based on their ability to generate all major blood cell types (red blood cells, platelets and immune cells).
This discovery of very early differentiating blood cells, Inlay said, may be very beneficial for the creation of HSC lines for clinical treatments.
"The hope is that by defining a set of markers that will allow us to make purer, cleaner populations of these precursor cells, we'll be able to reveal the key molecular events that lead to the emergence of the first HSCs in development. This could give us a step-by-step guide for creating these cells in a dish from pluripotent stem cell lines" added Inlay, who is an assistant professor of molecular biology & biochemistry at UC Irvine and conducted the study while a postdoctoral researcher in the Irving Weissman lab in the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.
###
The work was performed in collaboration with Thomas Serwold, now an assistant professor in the Joslin Diabetes Center at Harvard Medical School.
The research reported in this article was supported by the National Institutes of Health (grants 5 T32 AI07290, R01HL058770, R01CA86085 and U01HL09999), the California Institute for Stem Cell Research (grants T1-00001, RT2-02060 to I.L.W.), the Harvard Stem Cell Institute, the Siebel Stem Cell Institute, the Thomas and Stacey Siebel Foundation, and the Virginia and D.K. Ludwig Fund for Cancer Research.
Read the rest here:
Stem cell study finds source of earliest blood cells during development
Miami (PRWEB) March 21, 2014
Stem Cell Training, Inc., a division of the Global Stem Cells Group, and Bioheart, Inc. have announced the successful completion of their first joint stem cell training course held in the U.S.
Titled Adipose Derived Harvesting, Isolation and Re-integration Training Course, for the advancement of stem cell procedures, the two companies hosted 14 students in Miami for the training, conducted by Bioheart CSO Kristin Comella.
The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective in office regenerative medicine techniques.
Comella, Chief Scientific Officer for Bioheart, has more than 15 years experience in cell culturing and developing stem cell therapies for degenerative diseases, and experience in corporate entities, with expertise in regenerative medicine, training and education, research, product development and senior management.
The two companies will conduct 12 stem cell training courses in the U.S. during 2014. For more information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.
About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-dimensional company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.
The companys training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.
About the Global Stem Cells Group:
View post:
Stem Cell Training, Inc. and Bioheart, Inc. Complete First U.S.-based Stem Cell Training Course
Stem cell therapy -- beyond the headlines: Timothy Henry at TEDxGrandForks
There is considerable excitement about the use of stem cells for cardiovascular disease. Stem cells are unspecialized cells with the unique property to self-...
By: TEDx Talks
See original here:
Stem cell therapy -- beyond the headlines: Timothy Henry at TEDxGrandForks - Video
Hip conditions treated with Stem Cell Therapy and PRP
In this video, Ross Hauser, MD discusses some of the most common hip conditions that we treat at Caring Medical with Stem Cell Therapy and Platelet Rich Plas...
By: Caring Medical and Rehabilitation Services
Read the original:
Hip conditions treated with Stem Cell Therapy and PRP - Video
Traumatic brain injuries (TBI), sustained by close to 2 million Americans annually, including military personnel, are debilitating and devastating for patients and their families. Regardless of severity, those with TBI can suffer a range of motor, behavioral, intellectual and cognitive disabilities over the short or long term. Sadly, clinical treatments for TBI are few and largely ineffective.
In an effort to find an effective therapy, neuroscientists at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery in the USF Health Morsani College of Medicine, University of South Florida, have conducted several preclinical studies aimed at finding combination therapies to improve TBI outcomes.
In their study of several different therapies -- alone and in combination -- applied to laboratory rats modeled with TBI, USF researchers found that a combination of human umbilical cord blood cells (hUBCs) and granulocyte colony stimulating factor (G-CSF), a growth factor, was more therapeutic than either administered alone, or each with saline, or saline alone.
The study appeared in a recent issue of PLoS ONE.
"Chronic TBI is typically associated with major secondary molecular injuries, including chronic neuroinflammation, which not only contribute to the death of neuronal cells in the central nervous system, but also impede any natural repair mechanism," said study lead author Cesar V. Borlongan, PhD, professor of neurosurgery and director of USF's Center of Excellence for Aging and Brain Repair. "In our study, we used hUBCs and G-CSF alone and in combination. In previous studies, hUBCs have been shown to suppress inflammation, and G-CSF is currently being investigated as a potential therapeutic agent for patients with stroke or Alzheimer's disease."
Their stand-alone effects have a therapeutic potential for TBI, based on results from previous studies. For example, G-CSF has shown an ability to mobilize stem cells from bone marrow and then infiltrate injured tissues, promoting self-repair of neural cells, while hUBCs have been shown to suppress inflammation and promote cell growth.
The involvement of the immune system in the central nervous system to either stimulate repair or enhance molecular damage has been recognized as key to the progression of many neurological disorders, including TBI, as well as in neurodegenerative diseases such as Parkinson's disease, multiple sclerosis and some autoimmune diseases, the researchers report. Increased expression of MHCII positive cells -- cell members that secrete a family of molecules mediating interactions between the immune system's white blood cells -- has been directly linked to neurodegeneration and cognitive decline in TBI.
"Our results showed that the combined therapy of hUBCs and G-CSF significantly reduced the TBI-induced loss of neuronal cells in the hippocampus," said Borlongan. "Therapy with hUBCs and G-CSF alone or in combination produced beneficial results in animals with experimental TBI. G-CSF alone produced only short-lived benefits, while hUBCs alone afforded more robust and stable improvements. However, their combination offered the best motor improvement in the laboratory animals."
"This outcome may indicate that the stem cells had more widespread biological action than the drug therapy," said Paul R. Sanberg, distinguished professor at USF and principal investigator of the Department of Defense funded project. "Regardless, their combination had an apparent synergistic effect and resulted in the most effective amelioration of TBI-induced behavioral deficits."
The researchers concluded that additional studies of this combination therapy are warranted in order to better understand their modes of action. While this research focused on motor improvements, they suggested that future combination therapy research should also include analysis of cognitive improvement in the laboratory animals modeled with TBI.
See more here:
Stem cell combination therapy improves traumatic brain injury outcomes
PUBLIC RELEASE DATE:
20-Mar-2014
Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3303 University of South Florida (USF Innovation)
Tampa, FL (Mar. 20, 2014) Traumatic brain injuries (TBI), sustained by close to 2 million Americans annually, including military personnel, are debilitating and devastating for patients and their families. Regardless of severity, those with TBI can suffer a range of motor, behavioral, intellectual and cognitive disabilities over the short or long term. Sadly, clinical treatments for TBI are few and largely ineffective.
In an effort to find an effective therapy, neuroscientists at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery in the USF Health Morsani College of Medicine, University of South Florida, have conducted several preclinical studies aimed at finding combination therapies to improve TBI outcomes.
In their study of several different therapiesalone and in combinationapplied to laboratory rats modeled with TBI, USF researchers found that a combination of human umbilical cord blood cells (hUBCs) and granulocyte colony stimulating factor (G-CSF), a growth factor, was more therapeutic than either administered alone, or each with saline, or saline alone.
The study appeared in a recent issue of PLoS ONE.
"Chronic TBI is typically associated with major secondary molecular injuries, including chronic neuroinflammation, which not only contribute to the death of neuronal cells in the central nervous system, but also impede any natural repair mechanism," said study lead author Cesar V. Borlongan, PhD, professor of neurosurgery and director of USF's Center of Excellence for Aging and Brain Repair. "In our study, we used hUBCs and G-CSF alone and in combination. In previous studies, hUBCs have been shown to suppress inflammation, and G-CSF is currently being investigated as a potential therapeutic agent for patients with stroke or Alzheimer's disease."
Their stand-alone effects have a therapeutic potential for TBI, based on results from previous studies. For example, G-CSF has shown an ability to mobilize stem cells from bone marrow and then infiltrate injured tissues, promoting self-repair of neural cells, while hUBCs have been shown to suppress inflammation and promote cell growth.
The involvement of the immune system in the central nervous system to either stimulate repair or enhance molecular damage has been recognized as key to the progression of many neurological disorders, including TBI, as well as in neurodegenerative diseases such as Parkinson's disease, multiple sclerosis and some autoimmune diseases, the researchers report. Increased expression of MHCII positive cellscell members that secrete a family of molecules mediating interactions between the immune system's white blood cellshas been directly linked to neurodegeneration and cognitive decline in TBI.
View post:
USF study finds stem cell combination therapy improves traumatic brain injury outcomes
Stem Cells Blues No.1
By: gnakamura gkose
Read more from the original source:
Stem Cells Blues No.1 - Video
Embryonic Stem Cell Therapy
Short fun video about Stemaid #39;s Embryonic Stem Cells Visit http://www.stemaid.com.
By: stemaid
See the rest here:
Embryonic Stem Cell Therapy - Video
PUBLIC RELEASE DATE:
20-Mar-2014
Contact: Tan Yun Yun tan_yun_yun@a-star.edu.sg 656-826-6273 Biomedical Sciences Institutes (BMSI)
1. Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.
2. By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs. As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for basic research, drug discovery and cell therapy. In countries like Japan, USA and UK , a number of hiPSC bank initiatives have sprung up to make hiPSCs available for stem cell research and medical studies.
3. Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.
4. The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.
5. By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.
6. Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, "It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests."
7. Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper, said "We were able to differentiate the hiPSCs reprogrammed from Jonathan's finger-prick technique, into functional heart cells. This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."
See more here:
A*STAR scientists create stem cells from a drop of blood